冠心病患者超声治疗前后NO、GMP-140和vWF水平变化及其临床意义  

Changes of NO,GMP-140 and vWF in Patients with Coronary Heart Disease before and after Ultrasonic Therapy

作　　者：刘海陵[1] 阳小云[1] 侯敢[2] 

机构地区：[1]广东医学院附属医院内科门诊部,广东湛江524001 [2]广东医学院生化教研室

出　　处：《中国康复》2004年第4期209-210,共2页Chinese Journal of Rehabilitation

基　　金：湛江市科技攻关项目 (2 0 0 3 69)

摘　　要：目的 :探讨冠心病患者超声治疗前后一氧化氮 (NO)、α 颗粒膜蛋白 (GMP 14 0 )和vWF含量变化及临床意义。方法 :选用未使用抗血小板药治疗的冠心病患者 35例 (冠心病组 )进行超声治疗。采用硝酸还原酶法和ELISA双抗体夹心法测定治疗前后NO、GMP 14 0和vWF含量 ,并与正常组比较。结果 :血清NO水平、血浆GMP 14 0和vWF含量 ,超声治疗前冠心病组与正常组比较均显著升高 (P <0 .0 1) ,治疗后冠心病组NO水平及vWF含量接近正常组 ;血浆GMP 14 0有所下降 ,但 2组比较差异无显著性 ,且患者超声治疗前血清NO和血浆GMP 14 0、vWF呈显著正相关。结论 :冠心病患者体内存在血小板活化 ,并与NO可能共同参与了冠心病发展过程 ,超声治疗冠心病的机制可能是NO、GMP 14Objective: To study the changes of serum nitric oxide (NO), plasma granule membrane protein 140 (GMP 140) and von Willebrand factor (vWF) in patients with coronary heart disease(CHD) before and after ultrasonic therapy. Methods: Serum NO, plasma GMP 140 and vWF in patients with CHD and normal controls were measured by nitrate reductase method and double antibodies ELISA respectively before and after therapy. Results:The levels of serum NO, plasma GMP 140 and vWF in patients with CHD before ultrasonic therapy were significantly higher than those in normal group ( P <0.01), but decreased after therapy to some extent. NO and vWF levels were near normal,and the level of GMP 140 also decreased but the difference wasn't significant. Moreover serum NO level was positively correlated with plasma GMP 140 and vWF levels before ultrasonic therapy. Conclusion:There is an elevation of platelet activation in patients with CHD. It suggests that NO and platelet activation are associated with atherosclerosis and pathophysiologic progress of CHD in patients. And the mechanism in ultrasonic therapy of CHD may be related to the effects of NO, GMP 140 and vWF.

关 键 词：超声治疗 冠心病 一氧化氮 膜蛋白类 

分 类 号：R541.4[医药卫生—心血管疾病]